Summary: CRISPR/Cas9 is making gene-editing cheaper and easier than ever before, but the creators are embroiled in a fierce dispute over who holds the patents to CRISPR technology. We went to the U.S. Patent and Trademark Office to get the lowdown on this dispute and in this episode, after hearing attorneys duke it out, Ryan Cross explains how the kerfuffle developed, and what the possible outcomes of the impending decision mean.
